Related references
Note: Only part of the references are listed.CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2020 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2020)
A Paradigm Shift in the Treatment of Type 2 Diabetes and Heart Failure
Motoaki Sano
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2020)
Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline
Kacie Doyle-Delgado et al.
ANNALS OF INTERNAL MEDICINE (2020)
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Maria J. Pereira et al.
DRUGS (2019)
Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus
Maryam Rashid et al.
PAKISTAN JOURNAL OF MEDICAL SCIENCES (2019)
The direct effect of lobeglitazone, a new thiazolidinedione, on pancreatic beta cells: A comparison with other thiazolidinediones
Min Jeong Kwon et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management ... and potentially beyond
Andre J. Scheen
ANNALS OF TRANSLATIONAL MEDICINE (2019)
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
Mee Kyoung Kim et al.
DIABETES & METABOLISM JOURNAL (2019)
Empagliflozin: A Review in Type 2 Diabetes
James E. Frampton
DRUGS (2018)
Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
Eugene Han et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes
Molly G. Minze et al.
CURRENT DIABETES REVIEWS (2018)
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Daniel S. Hsia et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2017)
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Avivit Cahn et al.
DIABETES CARE (2016)
Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
Kyle T. Baron et al.
DIABETES THERAPY (2016)
Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
Kyle T. Baron et al.
DIABETES THERAPY (2016)
Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats
Jong-Hwa Lee et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Tolerability and Pharmacokinetics of Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor-γ Agonist, After a Single Oral Administration in Healthy Female Subjects
Min Kyu Park et al.
CLINICAL DRUG INVESTIGATION (2014)
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2014)
Prevention of Diabetes With Pioglitazone in ACT NOW Physiologic Correlates
Ralph A. DeFronzo et al.
DIABETES (2013)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects
Akiko Sarashina et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Tim Heise et al.
DIABETES THERAPY (2013)
Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Leo Seman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-γ Agonist: A Single- and Multiple-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects
Jung Won Kim et al.
CLINICAL THERAPEUTICS (2011)
PPAR-γ Agonists and Their Role in Type 2 Diabetes Mellitus Management
Valmore Bermudez et al.
AMERICAN JOURNAL OF THERAPEUTICS (2010)
Drug interactions evaluation: An integrated part of risk assessment of therapeutics
Lei Zhang et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
Thiazolidinediones and Cardiovascular Risk - A Question of Balance
Erland Erdmann et al.
CURRENT CARDIOLOGY REVIEWS (2009)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Epidemic obesity and type 2 diabetes in Asia
Kun-Ho Yoon et al.
LANCET (2006)
Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030
S Wild et al.
DIABETES CARE (2004)
Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability
ND Oakes et al.
DIABETES (2001)
Share Paper
